Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)

OBJECTIVES: The goal of this study was to compare the risk of cardiotoxicity with osimertinib versus all other drugs and versus epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitors (TKIs) (erlotinib, afatinib, and gefitinib) in the U.S. Food and Drug Administration Adverse Events Repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Anand, Kartik, Ensor, Joe, Trachtenberg, Barry, Bernicker, Eric H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352117/
https://www.ncbi.nlm.nih.gov/pubmed/34396179
http://dx.doi.org/10.1016/j.jaccao.2019.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352117/
https://www.ncbi.nlm.nih.gov/pubmed/34396179
http://dx.doi.org/10.1016/j.jaccao.2019.10.006

Ejemplares similares